StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
StageZero Life Sciences Ltd (SZLSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.001x
Based on the latest financial reports, StageZero Life Sciences Ltd (SZLSF) has a cash flow conversion efficiency ratio of -0.001x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.26K) by net assets ($-11.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
StageZero Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (1998–2022)
This chart illustrates how StageZero Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
StageZero Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of StageZero Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
XMax Inc.
NASDAQ:XWIN
|
-0.140x |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
N/A |
|
QuiaPEG Pharmaceuticals Holding AB
ST:QUIA
|
-0.115x |
|
Point of Care Nano-Technology Inc
PINK:PCNT
|
0.008x |
|
KARO INVEST a.s.
PR:KARIN
|
N/A |
|
Gudeng Equipment Co., LTD.
TWO:6953
|
N/A |
|
Regenbogen AG
F:RGB
|
0.022x |
|
KORAMCO The One REIT
KO:417310
|
N/A |
Annual Cash Flow Conversion Efficiency for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual cash flow conversion efficiency of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-7.50 Million | $-3.53 Million | 0.470x | +114.50% |
| 2021-12-31 | $2.76 Million | $-8.95 Million | -3.242x | -230.51% |
| 2020-12-31 | $-1.23 Million | $-3.06 Million | 2.484x | +143.05% |
| 2019-12-31 | $-4.49 Million | $-4.59 Million | 1.022x | +50.23% |
| 2018-12-31 | $-4.84 Million | $-3.29 Million | 0.680x | -46.33% |
| 2017-12-31 | $-3.02 Million | $-3.82 Million | 1.268x | +62.76% |
| 2016-12-31 | $-4.73 Million | $-3.68 Million | 0.779x | -20.01% |
| 2015-12-31 | $-1.77 Million | $-1.73 Million | 0.974x | +236.66% |
| 2014-12-31 | $2.15 Million | $-1.54 Million | -0.713x | +71.36% |
| 2013-12-31 | $1.74 Million | $-4.34 Million | -2.488x | -210.51% |
| 2012-12-31 | $5.07 Million | $-4.06 Million | -0.801x | -109.11% |
| 2011-12-31 | $-321.56K | $-2.83 Million | 8.800x | +131.32% |
| 2010-12-31 | $87.69K | $-2.46 Million | -28.100x | -1417.74% |
| 2009-12-31 | $2.49 Million | $-4.61 Million | -1.851x | +57.36% |
| 2008-12-31 | $1.73 Million | $-7.51 Million | -4.342x | -622.04% |
| 2007-12-31 | $13.81 Million | $-8.31 Million | -0.601x | -88.69% |
| 2006-12-31 | $19.54 Million | $-6.23 Million | -0.319x | -80.16% |
| 2005-12-31 | $5.93 Million | $-1.05 Million | -0.177x | +45.23% |
| 2004-12-31 | $7.69 Million | $-2.48 Million | -0.323x | -294.68% |
| 2003-12-31 | $5.74 Million | $-469.80K | -0.082x | +80.16% |
| 2002-12-31 | $1.71 Million | $-707.49K | -0.413x | +48.52% |
| 2000-12-31 | $2.32 Million | $-1.86 Million | -0.801x | -1079.69% |
| 1999-12-31 | $3.42 Million | $279.66K | 0.082x | +370.31% |
| 1998-12-31 | $165.36K | $-5.00K | -0.030x | -- |